Logo image of NEPH

NEPHROS INC (NEPH) Stock Fundamental Analysis

NASDAQ:NEPH - Nasdaq - US6406714005 - Common Stock - Currency: USD

2.15  -0.01 (-0.46%)

Fundamental Rating

3

Taking everything into account, NEPH scores 3 out of 10 in our fundamental rating. NEPH was compared to 128 industry peers in the Machinery industry. While NEPH seems to be doing ok healthwise, there are quite some concerns on its profitability. NEPH is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NEPH has reported negative net income.
NEPH had a negative operating cash flow in the past year.
In the past 5 years NEPH reported 4 times negative net income.
NEPH had negative operating cash flow in 4 of the past 5 years.
NEPH Yearly Net Income VS EBIT VS OCF VS FCFNEPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2M -4M -6M

1.2 Ratios

With a Return On Assets value of 0.66%, NEPH is not doing good in the industry: 66.41% of the companies in the same industry are doing better.
The Return On Equity of NEPH (0.86%) is worse than 66.41% of its industry peers.
NEPH has a worse Return On Invested Capital (0.05%) than 73.44% of its industry peers.
Industry RankSector Rank
ROA 0.66%
ROE 0.86%
ROIC 0.05%
ROA(3y)-26.57%
ROA(5y)-25.75%
ROE(3y)-50%
ROE(5y)-44.65%
ROIC(3y)N/A
ROIC(5y)N/A
NEPH Yearly ROA, ROE, ROICNEPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

NEPH has a Profit Margin of 0.52%. This is in the lower half of the industry: NEPH underperforms 66.41% of its industry peers.
The Operating Margin of NEPH (0.04%) is worse than 73.44% of its industry peers.
Looking at the Gross Margin, with a value of 61.59%, NEPH belongs to the top of the industry, outperforming 98.44% of the companies in the same industry.
NEPH's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 0.04%
PM (TTM) 0.52%
GM 61.59%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.79%
GM growth 5Y0.91%
NEPH Yearly Profit, Operating, Gross MarginsNEPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so NEPH is destroying value.
The number of shares outstanding for NEPH remains at a similar level compared to 1 year ago.
Compared to 5 years ago, NEPH has more shares outstanding
The debt/assets ratio for NEPH is higher compared to a year ago.
NEPH Yearly Shares OutstandingNEPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
NEPH Yearly Total Debt VS Total AssetsNEPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -10.81, we must say that NEPH is in the distress zone and has some risk of bankruptcy.
NEPH has a worse Altman-Z score (-10.81) than 92.19% of its industry peers.
NEPH has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
NEPH has a better Debt to Equity ratio (0.00) than 85.16% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.81
ROIC/WACC0
WACC10.48%
NEPH Yearly LT Debt VS Equity VS FCFNEPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M

2.3 Liquidity

NEPH has a Current Ratio of 5.31. This indicates that NEPH is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 5.31, NEPH belongs to the best of the industry, outperforming 92.97% of the companies in the same industry.
NEPH has a Quick Ratio of 3.64. This indicates that NEPH is financially healthy and has no problem in meeting its short term obligations.
NEPH's Quick ratio of 3.64 is amongst the best of the industry. NEPH outperforms 92.97% of its industry peers.
Industry RankSector Rank
Current Ratio 5.31
Quick Ratio 3.64
NEPH Yearly Current Assets VS Current LiabilitesNEPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

5

3. Growth

3.1 Past

NEPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 100.00%, which is quite impressive.
The Revenue has decreased by -0.58% in the past year.
NEPH shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.51% yearly.
EPS 1Y (TTM)100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150%
Revenue 1Y (TTM)-0.58%
Revenue growth 3Y11.49%
Revenue growth 5Y6.51%
Sales Q2Q%18.93%

3.2 Future

NEPH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10844260754.01% yearly.
The Revenue is expected to grow by 14.70% on average over the next years. This is quite good.
EPS Next Y587989967349491800%
EPS Next 2Y10844260754.01%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year17.25%
Revenue Next 2Y14.7%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NEPH Yearly Revenue VS EstimatesNEPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M
NEPH Yearly EPS VS EstimatesNEPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2019 2020 2021 2022 2023 2024 2025 2026 0 -0.2 -0.4 -0.6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

NEPH is valuated quite expensively with a Price/Forward Earnings ratio of 105.39.
71.09% of the companies in the same industry are cheaper than NEPH, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.50, NEPH is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 105.39
NEPH Price Earnings VS Forward Price EarningsNEPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

NEPH's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. NEPH is more expensive than 74.22% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 133.97
NEPH Per share dataNEPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

NEPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NEPH's earnings are expected to grow with 10844260754.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10844260754.01%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

NEPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEPHROS INC

NASDAQ:NEPH (5/19/2025, 4:30:02 PM)

2.15

-0.01 (-0.46%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)05-07 2025-05-07
Earnings (Next)08-06 2025-08-06
Inst Owners44.7%
Inst Owner Change-0.99%
Ins Owners11.86%
Ins Owner Change2.53%
Market Cap22.79M
Analysts82.5
Price Target4.59 (113.49%)
Short Float %0.09%
Short Ratio0.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)247.06%
Min EPS beat(2)198.04%
Max EPS beat(2)296.08%
EPS beat(4)3
Avg EPS beat(4)112.26%
Min EPS beat(4)-96.08%
Max EPS beat(4)296.08%
EPS beat(8)5
Avg EPS beat(8)45.65%
EPS beat(12)6
Avg EPS beat(12)6.09%
EPS beat(16)8
Avg EPS beat(16)4.46%
Revenue beat(2)1
Avg Revenue beat(2)2.43%
Min Revenue beat(2)-1.43%
Max Revenue beat(2)6.29%
Revenue beat(4)1
Avg Revenue beat(4)-5.02%
Min Revenue beat(4)-17.42%
Max Revenue beat(4)6.29%
Revenue beat(8)3
Avg Revenue beat(8)-2.09%
Revenue beat(12)4
Avg Revenue beat(12)-5.22%
Revenue beat(16)5
Avg Revenue beat(16)-4.69%
PT rev (1m)0%
PT rev (3m)-10%
EPS NQ rev (1m)0%
EPS NQ rev (3m)50%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)33.85%
Revenue NQ rev (3m)35.67%
Revenue NY rev (1m)7.17%
Revenue NY rev (3m)7.44%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 105.39
P/S 1.61
P/FCF N/A
P/OCF N/A
P/B 2.65
P/tB 3.14
EV/EBITDA 133.97
EPS(TTM)0
EYN/A
EPS(NY)0.02
Fwd EY0.95%
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS1.34
BVpS0.81
TBVpS0.69
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.66%
ROE 0.86%
ROCE 0.06%
ROIC 0.05%
ROICexc 0.08%
ROICexgc 0.11%
OM 0.04%
PM (TTM) 0.52%
GM 61.59%
FCFM N/A
ROA(3y)-26.57%
ROA(5y)-25.75%
ROE(3y)-50%
ROE(5y)-44.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.79%
GM growth 5Y0.91%
F-Score5
Asset Turnover1.26
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0.12
Cap/Depr 40.15%
Cap/Sales 0.39%
Interest Coverage 3
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.31
Quick Ratio 3.64
Altman-Z -10.81
F-Score5
WACC10.48%
ROIC/WACC0
Cap/Depr(3y)38.4%
Cap/Depr(5y)49.1%
Cap/Sales(3y)0.77%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150%
EPS Next Y587989967349491800%
EPS Next 2Y10844260754.01%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-0.58%
Revenue growth 3Y11.49%
Revenue growth 5Y6.51%
Sales Q2Q%18.93%
Revenue Next Year17.25%
Revenue Next 2Y14.7%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y100.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-172.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-159.49%
OCF growth 3YN/A
OCF growth 5YN/A